Thermo Fisher Scientific’s PPD clinical research business announced a strategic partnership with Datavant to enable privacy‑preserving tokenization and linkage of de‑identified patient data across more than 350 real‑world data partners and 80,000 US hospitals and clinics. The integration aims to enrich randomized trials with electronic medical record data and accelerate evidence generation for pharma and biotech customers. Thermo Fisher said the collaboration will support RWD enrichment for trial design, recruitment, and post‑market analytics by connecting consented research datasets and retrieving EMR data securely. The deal signals continued demand for interoperable, linked RWD solutions to inform clinical development and regulatory submissions.